Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice

Hypertension. 2010 Dec;56(6):1109-17. doi: 10.1161/HYPERTENSIONAHA.110.157412. Epub 2010 Oct 25.

Abstract

The development of cardiac hypertrophy in response to increased hemodynamic load and neurohormonal stress is initially a compensatory response that may eventually lead to ventricular dilatation and heart failure. Cellular FLICE-inhibitory protein (cFLIP) is a homologue of caspase 8 without caspase activity that inhibits apoptosis initiated by death receptor signaling. Previous studies showed that cFLIP expression was markedly decreased in the ventricular myocardium of patients with end-stage heart failure. However, the critical role of cFLIP on cardiac remodeling remains unclear. To specifically determine the role of cFLIP in pathological cardiac remodeling, we used heterozygote cFLIP(+/-) mice and transgenic mice with cardiac-specific overexpression of the human cFLIP(L) gene. Our results demonstrated that the cFLIP(+/-) mice were susceptible to cardiac hypertrophy and fibrosis through inhibition of mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2 signaling, whereas the transgenic mice displayed the opposite phenotype in response to angiotensin II stimulation. These studies indicate that cFLIP protein is a crucial component of the signaling pathway involved in cardiac remodeling and heart failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • CASP8 and FADD-Like Apoptosis Regulating Protein / genetics
  • CASP8 and FADD-Like Apoptosis Regulating Protein / metabolism*
  • Cardiomegaly / chemically induced
  • Cardiomegaly / metabolism*
  • Cardiomegaly / pathology
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
  • Fibrosis
  • Humans
  • Male
  • Mice
  • Mice, Transgenic
  • Myocardium / metabolism*
  • Myocardium / pathology
  • Vasoconstrictor Agents / pharmacology
  • Ventricular Remodeling*

Substances

  • CASP8 and FADD-Like Apoptosis Regulating Protein
  • Vasoconstrictor Agents
  • Angiotensin II
  • Extracellular Signal-Regulated MAP Kinases